April 5, 2022
A grown-up baby
It’s not often when a “new” company has nearly 100 years of experience but last Friday while we were fooling our subscribers BD parted with Embecta which began trading on the NASDAQ. Now we’ll say right from the start we would own this stock as we really don’t think it will remain an independent company for too long. How long will it take before they are gobbled up not sure about that, but this is going to happen.
Embecta has perhaps the simplest most straight forward business model in diabetes. They make boatloads of money by . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.